Xillix Technologies Corp.
TSX : XLX

Xillix Technologies Corp.

November 09, 2005 11:48 ET

Xillix Supports November Lung Cancer Awareness Month

RICHMOND, BRITISH COLUMBIA--(CCNMatthews - Nov. 9, 2005) - Xillix Technologies Corp. (TSX:XLX), the world leader in fluorescence endoscopy for the early detection of cancer, today announced some of its recent activities in support of November's Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer death in both men and women with a poor 15% five-year survival rate. The U.S. Food and Drug Administration (FDA) recently approved the Company's latest device, Onco-LIFE™ for use in the detection of lung cancer. FDA approval of Onco-LIFE followed an international multi-center clinical trial which demonstrated that Onco-LIFE improved the detection of subtle early stage lung cancer (carcinoma in situ or Stage 0) and precancerous lesions (moderate-severe dysplasia) by 325% compared to conventional white-light endscopy alone.

"Onco-LIFE brings new hope in the fight against lung cancer by allowing physicians to see lung cancer earlier, enabling better intervention. Even in known lung cancer patients who are at risk for recurrent disease and secondary lesions, Onco-LIFE improved detection," said Cynthia Roney, President and CEO. "Now that we have FDA approval for Onco-LIFE, we are able to more actively support lung cancer initiatives, especially in the U.S. where interest in lung cancer is increasing significantly."

From October 30th to November 2nd, Xillix presented Onco-LIFE to leading pulmonologists and thoracic surgeons attending The American College of CHEST Physicians in Montreal (CHEST). This was the first North American pulmonology conference following FDA approval of Onco-LIFE on June 30th 2005. Xillix and the Company's distribution partner ConMed, both had Onco-LIFE devices on display and the sales teams provided hands-on demonstrations to the physicians attending the conference. A separate interactive physician-led Onco-LIFE demonstration was also presented during the 13th Annual Assembly of the American Association for Bronchology on October 30th, allowing the opportunity for physicians to learn directly from other physicians experienced with Onco-LIFE. Also during CHEST, on October 31st, Xillix held its first analyst luncheon meeting to allow participants to hear about the global commercialization of Onco-LIFE, including physician feedback regarding lung cancer, autofluorescence and Onco-LIFE. The meeting was well attended with institutional investors, representatives from six leading financial biotech analysts and three seasoned Onco-LIFE physicians. An archived webcast of the presentation is available on the Xillix website at www.xillix.com.

On November 3rd, CNN Television aired an interview with reporter Soledad O'Brien and Dr. Harvey Pass, who is a thoracic surgeon at New York University Medical Center and an experienced Xillix LIFE-Lung™ physician and Onco-LIFE investigator. Dr. Pass was interviewed by CNN to gain insight into the clinical challenges of lung cancer. Dr. Pass specifically mentioned autofluorescence and its role in the early detection of lung cancer. International media coverage on lung cancer is expected to increase in support of November's Lung Cancer Awareness Month and several Onco-LIFE physicians have agreed to participate as expert contacts.

On November 5th, Xillix began to air its corporate profile focused on the lung cancer application of Onco-LIFE on Business Television, a half-hour weekly national business program profiling emerging technologies across North America. This program segment may be re-broadcast and the video is currently available on the Xillix website.

The U.S. based journal 'Coping with Cancer' November-December issue is focused on lung cancer and will be disseminated to 1,000 cancer centers in the U.S. Xillix has provided a corporate message in the November-December issue in support of November's Lung Cancer Awareness Month. The corporate message may be re-published and is currently available on the Xillix website.

From November 3rd to 5th, Xillix exhibited Onco-LIFE at the BC Cancer Agency (BCCA) Annual Cancer Conference held in Vancouver. More than 800 delegates attended and were able to see the progress made in the development of Xillix LIFE technology since it was transferred to Xillix from BCCA in 1991. Xillix continues to conduct its lung cancer development activities at the BCCA with Dr. Stephen Lam, Chair of the BCCA Lung Tumor Group and Xillix Medical Advisor, and Dr. Annette McWilliams, who assisted with the recent CHEST meetings.

"Lung cancer kills more people than breast, prostate, colon, liver, melanoma and kidney cancers combined. Smoking cessation programs are essential, but alone are not enough when we consider that in the U.S. there are 45 million former smokers who will always be at an elevated risk for lung cancer, and the fact that 60% of all new lung cancer patients are former smokers or non-smokers," said Ms. Roney. "The key to improved lung cancer survival is better detection and Onco-LIFE is a proven and powerful new tool. We look forward to putting Onco-LIFE in the skilled hands of physicians and together increasing lung cancer awareness with the goal of improving patient survival. We are determined to make a difference in the lives of lung cancer patients."

Xillix has recently added new material to its website including physician feedback and supplementary information to highlight the Company's role in the fight against lung cancer. This information, and the content mentioned above, is available at www.xillix.com/media.cfm.

About Xillix

Xillix Technologies Corp. is a Canadian medical device company and the world leader in fluorescence endoscopy for improved cancer detection. Xillix's latest device, Onco-LIFE™, incorporates fluorescence and white-light endoscopy in a single device that has been developed for the detection and localization of lung and gastrointestinal (GI) cancers. An international multicenter lung cancer clinical trial of Onco-LIFE demonstrated a 325% per-lesion improvement in the detection of early lung cancer (moderate-severe dysplasia and carcinoma in situ) and a 250% per-patient improvement compared to white-light alone. Onco-LIFE is approved for sale in the United States for the lung application and in Europe and Canada for both lung and GI applications. Onco-LIFE is compact, user-friendly and is compatible with a wide range of endoscopes and endoscopic accessories to help maximize global market acceptance.

Note: Certain of the statements contained in this press release contain forward-looking statements which involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The Company does not expect to update forward-looking statements continually as conditions change. Investors are referred to the full discussion of risk factors associated with the Company's business contained in the Company's Annual Information Form filed with securities regulatory authorities dated March 31, 2005.

The Company is listed on the Toronto Stock Exchange under the trading symbol "XLX".

Contact Information